SUMMIT THERAPEUTICS
(NASDAQ: SMMT)

Summit Therapeutics plc, formerly Summit Corporation plc, is a United Kingdom-based drug discovery and development company. The Company is engaged in developing drug candidates to treat Duchenne Muscular Dystrophy (DMD), a genetic disease, and Clostridium difficile Infection (CDI), an infectious disease. The Company is developing a pipeline of utrophin modulators that comprise its lead candidate SMT C1100 and next generation modulators that are at an earlier stage of development. SMT C1100 is in a Phase 1b clinical trial. The Company is developing SMT19969 as an antibiotic that is a potential treatment for initial CDI that could significantly reduce rates of recurrent disease. SMT19969 completed a Phase 1 clinical trial in healthy volunteers with the results showing it to be safe and well tolerated at all doses tested, including the expected therapeutic dose. The Company�s subsidiaries include Summit (Oxford) Limited and Summit (Wales) Limited.

17.870

-0.530 (-2.88%)
Range 17.710 - 18.603   (5.04%)
Open 18.125
Previous Close 18.400
Bid Price 1.590
Bid Volume 13
Ask Price 1.600
Ask Volume 40
Volume 6,597,547
Value -
Remark
Delayed prices. Updated at 21 Dec 2024 05:00.
Data powered by
View All Events

About SUMMIT THERAPEUTICS INC

Summit Therapeutics plc, formerly Summit Corporation plc, is a United Kingdom-based drug discovery and development company. The Company is engaged in developing drug candidates to treat Duchenne Muscular Dystrophy (DMD), a genetic disease, and Clostridium difficile Infection (CDI), an infectious disease. The Company is developing a pipeline of utrophin modulators that comprise its lead candidate SMT C1100 and next generation modulators that are at an earlier stage of development. SMT C1100 is in a Phase 1b clinical trial. The Company is developing SMT19969 as an antibiotic that is a potential treatment for initial CDI that could significantly reduce rates of recurrent disease. SMT19969 completed a Phase 1 clinical trial in healthy volunteers with the results showing it to be safe and well tolerated at all doses tested, including the expected therapeutic dose. The Company�s subsidiaries include Summit (Oxford) Limited and Summit (Wales) Limited.

Loading Chart...

Please login to view stock data and analysis